Can glucagon‑like peptide‑1 receptor agonists (e.g., liraglutide, semaglutide, dulaglutide) worsen pre‑existing gallstones?

GLP-1 Receptor Agonists and Gallstone Disease

GLP-1 receptor agonists do not worsen pre-existing gallstones directly, but they significantly increase the risk of developing new gallbladder and biliary disease, including gallstone formation, cholecystitis, and complications requiring cholecystectomy. The evidence consistently demonstrates this is a class effect that becomes more pronounced with higher doses, longer duration of use, and particularly when used for weight loss rather than diabetes management alone.

The Core Problem: New Gallbladder Disease, Not Worsening of Existing Stones

The available evidence addresses gallbladder disease development rather than progression of pre-existing gallstones specifically. However, the mechanisms and clinical data suggest important considerations:

Evidence from Clinical Trials

The most comprehensive meta-analysis of 76 randomized controlled trials involving 103,371 patients found GLP-1 RA use was associated with:

• 37% increased risk of gallbladder or biliary diseases overall (RR 1.37,95% CI 1.23-1.52) 1
• 27% increased risk of cholelithiasis specifically (RR 1.27,95% CI 1.10-1.47) 1
• 36% increased risk of cholecystitis (RR 1.36,95% CI 1.14-1.62) 1
• 55% increased risk of biliary disease (RR 1.55,95% CI 1.08-2.22) 1

The LEADER trial specifically examining liraglutide demonstrated a 60% increased risk of acute gallbladder or biliary disease compared to placebo (HR 1.60,95% CI 1.23-2.09, P<0.001), with cholecystectomy performed 56% more frequently (HR 1.56,95% CI 1.10-2.20) 2.

Critical Risk Factors

The risk is NOT uniform—it varies dramatically based on:

Dose-dependent effect:

• Higher doses: RR 1.56 (95% CI 1.36-1.78)
• Lower doses: RR 0.99 (95% CI 0.73-1.33)
• P=0.006 for interaction 1

Duration-dependent effect:

• Longer duration: RR 1.40 (95% CI 1.26-1.56)
• Shorter duration: RR 0.79 (95% CI 0.48-1.31)
• P=0.03 for interaction 1

Indication matters profoundly:

• Weight loss indication: RR 2.29 (95% CI 1.64-3.18)
• Type 2 diabetes indication: RR 1.27 (95% CI 1.14-1.43)
• P<0.001 for interaction 1

Mechanism: Why This Happens

GLP-1 receptor agonists cause delayed gastric emptying as a core pharmacodynamic effect 3. This mechanism extends to the biliary system through:

1. Reduced gallbladder motility - The delay in gastric emptying reflects broader effects on GI motility
2. Bile stasis - Slower gallbladder emptying promotes bile concentration and stone formation
3. Cholecystokinin suppression - Altered signaling affects gallbladder contractility 4

The FDA drug label for liraglutide explicitly lists "gallbladder disorders" as a common adverse effect, noting they are "unusual to be symptomatic" 5, 3.

Clinical Implications for Patients with Pre-existing Gallstones

If a patient has known asymptomatic gallstones:

• The medication increases risk of complications (cholecystitis, biliary obstruction) through reduced gallbladder motility and bile stasis
• Risk is highest in the first 120 days after treatment initiation 6
• Women and patients >60 years face elevated risk 6
• Liraglutide carries higher risk than dulaglutide in real-world data 6

Perioperative Considerations

The 2024-2025 guidelines emphasize that GLP-1 RAs cause delayed gastric emptying with uncertain effects on gallbladder function 7, 5. While these guidelines focus on aspiration risk, the same mechanisms affect biliary motility. Gallbladder disorders are listed as requiring monitoring but are noted to be "unusual to be symptomatic" 5, 5.

Practical Management Algorithm

For patients considering GLP-1 RA therapy:

1. Screen for gallbladder disease history before initiating therapy

2. If asymptomatic gallstones present:

   • Discuss 37-60% increased risk of complications
   • Consider alternative therapies (SGLT2 inhibitors show no increased risk 6)
   • If proceeding, use lowest effective dose
   • Educate on biliary colic symptoms (right upper quadrant pain, nausea after fatty meals)

3. If symptomatic gallstones present:

   • Strongly consider cholecystectomy before initiating GLP-1 RA
   • If surgery declined, GLP-1 RAs are relatively contraindicated

4. During therapy:

   • Monitor for biliary symptoms, especially first 4 months
   • Lower threshold for imaging if symptoms develop
   • Consider dose reduction if tolerable for glycemic/weight goals

Common Pitfall to Avoid

Do not assume the risk is negligible because gallbladder disorders are listed as "unusual to be symptomatic" in drug labels 5. This refers to baseline incidence, not the relative risk increase. The absolute risk increase translates to approximately 2-6 additional cases per 1000 patient-years depending on indication and dose 2, 8.

The Bottom Line

GLP-1 receptor agonists create a pro-lithogenic environment through delayed gastric emptying and reduced gallbladder motility. While they don't directly "worsen" existing stones in the sense of making them larger, they substantially increase the risk that asymptomatic stones become symptomatic or complicated. This risk is dose-dependent, duration-dependent, and particularly pronounced when used for weight loss. Patients with known gallstones should be counseled about this 37-129% increased risk of biliary complications, and prophylactic cholecystectomy should be considered for symptomatic stones before initiating therapy.